



ASX ANNOUNCEMENT

26 JULY 2019

CANN SECURES MANUFACTURING LICENCES FOR EXISTING FACILITIES

26 July 2019 – Cann Group Limited (ASX: CAN) announced that the Federal Department of Health’s Office of Drug Control (ODC) yesterday approved manufacturing licences for the Company’s existing Northern and Southern medicinal cannabis facilities in Melbourne.

The licences relate to the manufacturing, packaging, storage, transport and disposal of medicinal cannabis in final dose and intermediate forms. Appropriate permits will be required in relation to the undertaking of specific activities under the licences.

Cann Group now holds all cultivation, production and manufacture licences under the Narcotics Drugs Act, along with import and export licences under the Customs Act.

Cann Group CEO, Peter Crock, said: “Securing our ODC manufacturing licences is an important milestone that supports our fully integrated business model strategy. The ability to undertake these activities at both our Northern and Southern facilities gives us considerable flexibility as we continue to progress the development of our new state-of-the-art cultivation facility near Mildura.”

Mr Crock said the licences will complement the manufacturing arrangements in place with IDT Australia Ltd, which was granted its ODC manufacturing licence in May.

“IDT, which has GMP approved facilities, offers us immediate access to proven expertise in pharmaceutical manufacturing while we continue to develop our own capabilities.”

For further information please contact:

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 498 000 762
clive.fanning@canngrouponlimited.com

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Cann Group

Cann Group is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia. The company has established research and cultivation facilities in Melbourne and is striving to provide access to medicinal cannabis for Australian patients. Cann Group has executed collaboration agreements that will enable it to establish a leading position in plant genetics, breeding, extraction, analysis and production techniques required to facilitate the supply of medicinal cannabis for a range of diseases and medical conditions. It was issued with Australia’s first medicinal cannabis research licence in February 2017, in addition to Australia’s first medicinal cannabis cultivation licence in March 2017. Aurora Cannabis Inc – one of Canada’s largest listed medicinal cannabis companies – is a cornerstone investor in Cann, with a 22.9% shareholding.